NCT00363649View on ClinicalTrials.gov

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Leukemia
Interventions
BIOLOGICAL

GM-K562 cell vaccine

Given by injection

BIOLOGICAL

Interferon alfa

Given by injection

BIOLOGICAL

Sargramostim

Given by injection

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00363649 - Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI | Biotech Hunter | Biotech Hunter